Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105

Journal of Clinical Oncology

Volumn 26, Issue 15, 2008, Pages 2457-2463

  Socinski, Mark A ^a   Blackstock, A William ^a   Bogart, Jeffrey A ^a   Wang, Xiaofei ^a   Munley, Michael ^a   Rosenman, Julian ^a   Gu, Lin ^a   Masters, Gregory A ^a   Ungaro, Peter ^a   Sleeper, Arthur ^a   Green, Mark ^a   Miller, Antonius A ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; PLACEBO;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG DOSE REDUCTION; EDEMA; ESOPHAGITIS; FATIGUE; FEMALE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; COMPUTER ASSISTED RADIOTHERAPY; FOLLOW UP; LUNG TUMOR; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RADIOGRAPHY; REMISSION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THORAX TUMOR;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PLACEBOS; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; REMISSION INDUCTION; SURVIVAL RATE; THORACIC NEOPLASMS;

EID: 45149128875     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.7371     Document Type: Article

References (40)

1. American Cancer Society: Cancer Facts and Figures 2006. http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf
2. Socinski MA, Morris DE, Masters GA, et al: Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123:226S-243S, 2003
3. Socinski MA, Zhang C, Herndon J, et al: Combined modality trials of the Cancer and Leukemia Group B in stage III non-small lung cancer: Analysis of factors influencing survival and toxicity. Ann Oncol 15:1033-1041, 2004
4. Curran D, Scott C, Langer C, et al: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22:621, 2003 (abstr 2499)
5. Fournel P, Robinet G, Thomas P, et al: Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23:5910-5917, 2005
6. Furuse K, for the West Japan Lung Cancer Group: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
7. Zatloukal P, Petruzelka L, Zemanova M, et al: Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer: A randomized phase II study. Proc Am Soc Clin Oncol 21:290a, 2002 (abstr 1159)
8. Akerley W, Herndon JE Jr, Lyss AP, et al: Induction paclitaxel/ carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: A limited-access study-CALGB 9534. Clin Lung Cancer 7:47-53, 2005
9. Belani CP, Choy H, Bonomi P, et al: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multimodality protocol. J Clin Oncol 23:5883-5891, 2005
10. Movsas B, Scott C, Langer C, et al: Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyper-fractionated radiation: Radiation Therapy Oncology Group trial 98-01. J Clin Oncol 23:2145-2154, 2005
11. Vokes EE, Herndon JE 2nd, Kelley MJ, et al: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698-1704, 2007
12. Perez CA, Pajak TF, Rubin P, et al: Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: Report by the Radiation Therapy Oncology Group. Cancer 59:1874-1881, 1987
13. Perez CA, Stanley K, Grundy G, et al: Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: Report by the Radiation Therapy Oncology Group. Cancer 50:1091-1099, 1982
14. Russo S, Rosenman J: General aspects of radiotherapy for lung cancer, in Detterbeck FC, Rivera MP, Socinski MA, et al (eds): Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA, WB Saunders, 2001, pp 148-161
15. Lee CB, Stinchcombe TE, Rosenman JG, et al: Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: Evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer 8:195-202, 2006
16. Manon RR, Jaradat H, Patel R, et al: Potential for radiation therapy technology innovations to permit dose escalation for non-small-cell lung cancer. Clin Lung Cancer 7:107-113, 2005
17. Claude L, Perol D, Ginestet C, et al: A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: Clinical and dosimetric factors analysis. Radiother Oncol 71:175-181, 2004
18. Graham MV, Purdy JA, Emami B, et al: Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45:323-329, 1999
19. Senan S, De Ruysscher D: Critical review of PET-CT for radiotherapy planning in lung cancer. Crit Rev Oncol Hematol 56:345-351, 2005
20. Yorke ED, Jackson A, Rosenzweig KE, et al: Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 54:329-339, 2002
21. Socinski MA, Rosenman JG, Halle JS, et al: Induction carboplatin/ paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B non-small cell lung cancer: A modified phase I trial. Cancer 89:534-542, 2000
22. Socinski MA, Rosenman JG, Halle JS, et al: Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B non-small cell lung carcinoma: A modified phase I/II trial. Cancer 92:1213-1223, 2001
23. Rosenman JG, Halle JS, Socinski MA, et al: High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54:348-356, 2002
24. Socinski MA, Halle JS, Morris DE, et al: Long-term results of aggressive combined modality therapy employing induction and concurrent carboplatin/paclitaxel with dose-escalated thoracic conformal radiation therapy. Lung Cancer 41:S239, 2003 (suppl 2; abstr P-585)
25. Socinski MA, Morris DE, Halle JS, et al: Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: A dose-escalation phase I trial. J Clin Oncol 22:4341-4350, 2004
26. Belderbos JS, De Jaeger K, Heemsbergen WD, et al: First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 66:119-126, 2003
27. Blackstock AW, Lesser GJ, Fletcher-Steede J, et al: Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 51:1281-1289, 2001
28. Blackstock AW, Ho C, Butler J, et al: Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. J Thorac Oncol 1:434-440, 2006
29. Bradley JD, Graham MV, Winter KW, et al: Acute and late toxicity results of RTOG 9311: A dose escalation study using 3D conformal radiation therapy in patients with inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 57:S137-S138, 2003
30. Schild SE, McGinnis WL, Graham D, et al: Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 65:1106-1111, 2006
31. Sim S, Rosenzweig KE, Schindelheim R, et al: Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 51:660-665, 2001
32. Wu KL, Jiang GL, Liao Y, et al: Three-dimensional conformal radiation therapy for non-small-cell lung cancer: A phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys 57:1336-1344, 2003
33. Marks LB, Garst J, Socinski MA, et al: Carboplatin/ paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: Report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol 22:4329-4340, 2004
34. Calvert A, Newell D, Gumbrell L, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
35. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
36. Vokes EE, Herndon JE 2nd, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20:4191-4198, 2002
37. Ready N, Herndon J, Vokes E, et al: Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small-cell lung cancer (NSCLC): A CALGB stratified phase II trial. J Clin Oncol 22:7078, 2004
38. Bradley JD, Graham M, Suzanne S, et al: Phase I results of RTOG L-0117: A phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with Inoperable NSCLC. J Clin Oncol 23:636s, 2005 (abstr 7063)
39. Lee CB, Socinski MA, Lin L, et al: High-dose 3D chemoradiotherapy trials in stage III non-small-cell lung cancer (NSCLC) at the University of North Carolina: Long-term follow up and late complications. J Clin Oncol 24:400s, 2006 (abstr 7145)
40. Miller KL, Shafman TD, Anscher MS, et al: Bronchial stenosis: An underreported complication of high-dose external beam radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys 61:64-69, 2005